KR20140083425A - Pharmaceutical composition comprising eriodictyol or its pharmaceutically acceptable salts as an active ingredient for preventing or treating contact dermatitis - Google Patents

Abstract

The present invention relates to a pharmaceutical composition, a skin external application, a cosmetic composition, and a health functional food including an eriodictyol compound or a pharmaceutically acceptable salt of the same as an active ingredient for preventing or treating contact dermatitis. In particular, the eriodictyol compound or pharmaceutically acceptable salt of the same exhibits an effect in controlling the generation of IgE in contact dermatitis caused by 2,4-dinitrochlorobenzene (DNCB) which is the antigen of delayed type hypersensitivity reaction, and decreases scratching actions, skin functions, and skin thickness for all of the epithelium, corium, and skin increased by DNCB, so that the eriodictyol compound or pharmaceutically acceptable salt of the same can be usefully used as a pharmaceutical composition, a skin external application, a cosmetic composition, and a health functional food.

Description

[0001] The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis, which comprises, as an active ingredient, an erythropyrimidine compound or a pharmaceutically acceptable salt thereof,

The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis containing an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

In the modern society, the incidence of skin diseases including allergic contact dermatitis is greatly increased due to the increase of environmental pollution and the production of synthetic materials due to the development of industry. In addition, urban people are increasingly exposed to allergic reactions caused by various external antigens, such as ticks, dusts that increase as humidity decreases, pet hair, pollen, new fruits and foods, as the living environment changes to westernization.

Allergic reactions caused by these various antigens are considered to be one of the causes of infant asthma, atopic dermatitis, rhinitis, urticaria, eczema, etc. Antigens causing allergic contact dermatitis are increasingly encountered in everyday life Trend.

Contact dermatitis refers to all dermatitis caused by contact with foreign substances, including contact dermatitis irritant contact dermatitis, allergic contact dermatitis, allergic contact dermatitis, Allergic contact dermatitis and contact urticaria syndrome.

The causes of allergic contact dermatitis include plants, metals, cosmetics, preservatives, medicines, rubber, and synthetic resins. The most common cause of dermatitis among plants is lacquer trees. It can also occur when using lacquer as well as wild raspberry juice. Systemic eczematous contact dermatitis, which causes systemic erythema (round red dot) after eating lacquer chicken, is often observed. Representative materials that cause allergic contact dermatitis among metals are nickel, chromium, cobalt and mercury. Symptoms of allergic contact dermatitis are eczematous lesions with mainly erythema (round red dot) and edema. In some, acne lesions, urticaria lesions, erythema multiforme, pigmentation, and granulomatous lesions may also occur.

Allergic contact dermatitis is characterized by the appearance of redness, papules, small spots and ulcers on the localized areas where the antigen has been contacted. The allergic contact dermatitis belongs to a delayed type hypersensitivity reaction in which symptoms are expressed by the sensitization process of allergic antigens and the re- It is an immune disease. Allergic contact dermatitis after the contact antigen that is passed to the Langerhans (Langerhans) cells through a unique process, the antigen is delivered to the T _H cells l (Helper T cell 1) to divide the the T _H cell memory cells (memory cell ) To form a sensitizing process. When the antigen is re-sensitized, the inflammation reaction and tissue damage are induced to manifest symptoms, and many cytokines such as IgE are released during this process.

As the industrialization accelerates, modern people are exposed to allergens of various types, and as the possibility of skin disease caused by allergy and atopy increases, it becomes a social problem. Therefore, a substance which can alleviate the allergic reaction from natural substances with low side effects . However, systematic studies are still lacking in this area.

On the other hand, the eriodictyol compound is a kind of plant flavanone which is a component separated from Painted maple ( Acer mono Max.) And Yerba santa ( Eriodictyon califonicum ) It is known.

The eriodic thiol compound has been reported to have a preventive effect on diseases such as arteriosclerosis and hypertension. However, it has not been reported that an eriodic thiol compound has an effect on treating contact dermatitis-related diseases.

Techniques for the anti-inflammatory effect of eriodictyol using the macrophage cell line Raw 264.7 are known. However, the above-mentioned references disclose NO analysis, ONOO ^- formation inhibition assay, phagocytosis assay, and inflammation-inducing cytokine level measurement analysis of eriodictyol- inflammatory cytokines) have just been disclosed.

As another document, there is known a technique for a composition containing, as an active ingredient, a fungus extract, a fraction thereof, or a compound isolated from the fraction. However, the above document discloses that 5,7-Dihydroxy-6-geranyl flavanone is a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of obesity, And can be used for prevention and treatment.

Accordingly, the present inventors have completed the present invention by confirming that an eriodictyol compound, which is a kind of flavanone in plants, has an effect of relieving itching and inflammation of contact dermatitis.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating contact dermatitis containing an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Another object of the present invention is to provide an external preparation for skin for preventing or treating contact dermatitis, which comprises an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for improving or alleviating contact dermatitis containing an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

Another object of the present invention is to provide a health functional food for improving or alleviating contact dermatitis containing an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

In order to achieve the above object, the present invention provides an eriodictyol compound which can be used for the relief of itching and the inflammation-relieving effect of allergic contact dermatitis induced by the application of antigen DNCB (2.4-dinitrochlorobenzene) Or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating contact dermatitis.

The present invention also provides an external preparation for skin for preventing or treating contact dermatitis comprising an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention also provides a cosmetic composition for improving or alleviating contact dermatitis containing an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention also provides a health functional food for improving or alleviating contact dermatitis containing an eriodictyol compound or a pharmaceutically acceptable salt thereof as an active ingredient.

The eriodictyol or pharmaceutically acceptable salt thereof according to the present invention has an effect of inhibiting the production of IgE in contact dermatitis induced by a delayed hypersensitivity antigen (DNCB (2,4-dinitrochlorobenzene)) , A scratching effect on the entire epithelium, dermis and skin by the DNCB, a skin sensation and a skin thickness reduction effect, a pharmaceutical composition for preventing and treating contact dermatitis, a skin external preparation, a cosmetic composition and a health functional food Can be usefully used.

Brief Description of the Drawings Fig. 1 is a graph showing the results of measurement of changes in the scratching behavior of the dorsal skin of mice induced with allergic contact dermatitis according to the treatment of the erio-thyroid compound of the present invention. Fig.
FIG. 2 is a graph showing skin sensory evaluation results of dorsal epidermis of an allergic contact dermatitis-induced mouse according to the treatment of an erio-thiol thiol compound of the present invention.
FIG. 3 is a photograph of the dorsal epidermal tissue of a mouse induced by allergic contact dermatitis induced by the treatment of the erio-dide thiol compound of the present invention, followed by hematoxylin and eosin staining, followed by microscopic observation. (A magnification of 40 times magnification and a magnification of 100 magnification, respectively).
FIG. 4 is a graph showing the results of measurement of the change in serum IgE according to the treatment with an erio-thiol compound of the present invention. FIG.

The present invention provides a pharmaceutical composition for preventing or treating contact dermatitis comprising an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:

[Chemical Formula 1]

.

.

In the present invention, the eriodictyol compound is a kind of flavanone, and its IUPAC name is (2S) -2- (3,4-dihydroxyphenyl) -5,7-dihydroxy-4-chromanone, Has a molecular formula of C ₁₅ H ₁₂ O ₆ and a molecular weight of 288.25.

The erio-thiol compound according to the present invention may be used in the form of a salt, preferably a pharmaceutically acceptable salt, wherein the salt is preferably an acid addition salt formed by a pharmaceutically acceptable free acid And the free acid may be an organic acid or an inorganic acid. The organic acids include, but are not limited to, citric, acetic, lactic, tartaric, maleic, fumaric, formic, propionic, oxalic, trifluroacetic, benzoic, gluconic, methosulfonic, glycolic, succinic, Glutamic acid and aspartic acid. The inorganic acid includes, but is not limited to, hydrochloric acid, bromic acid, sulfuric acid, and phosphoric acid.

In addition, the erio-thiol compound of the present invention can be isolated from natural materials or can be prepared by a chemical synthesis method known in the art, and commercially available erio-thiol thiol compounds can be commercially obtained and used.

In addition, the pharmaceutical composition of the present invention has almost no toxicity and is harmless to the human body because it contains a component separated from a natural product extract or a derivative thereof as an active ingredient.

The pharmaceutical dosage forms of the eriodic thiols according to the present invention may be used in the form of their pharmaceutically acceptable salts and may also be used alone or in combination with other pharmaceutically active compounds as well as in suitable aggregates.

In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of contact dermatitis characterized by relieving itching.

In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for preventing or treating contact dermatitis characterized by inhibiting an inflammatory reaction.

The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier. The composition comprising a pharmaceutically acceptable carrier can be of various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.

Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used.

Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have.

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The pharmaceutical composition may be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze- It can have one formulation.

In one embodiment of the present invention, the present invention provides an external preparation for skin for preventing or treating contact dermatitis comprising an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient :

 [Chemical Formula 1]

.

.

In one embodiment of the present invention, the external preparation for skin is formulated into any one selected from the group consisting of ointments, creams, lotions, liquids, dressings, patches, foams, tapes, aerosols, external powders and spraying agents .

The amount of the erodic thiol varies depending on the preparation. For example, 0.01 to 1 w / v% in the case of ointments, creams, gels and lotions, 0.01 to 2 w / v% in the case of the foaming agent and 0.01 to 2 w / v%, and 0.01 to 2 w / v% in the case of an external preparation.

Other ingredients than the active ingredient of the formulation of the present invention may be any ingredient commonly used in external preparations. In the case of ointments, creams, gels and lotions, there may be used white petrolatum (vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane A mechanism such as; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, hexyllaurate, fatty acid, fatty acid ester, vegetable oil, Solvents or stabilizers such as alcohols; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin; Thickeners such as carboxyvinyl polymer, xanthan gum, carboxymethylcellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Preservatives; Adsorption promoters; And other suitable fillers may be added.

In the case of the blowing agent, an adhesive such as a polyacrylic acid and a polyacrylic acid copolymer; A crosslinking agent such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, magnesium aluminometasilicate and dihydroxy aluminum aminoacetate; Thickening agents such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Polyhydric alcohols such as glycerin, polyethylene glycol (macrogol), polyethylene glycol and 1,3-butanediol; Surfactants such as polyoxyethylene derivatives; fragrances such as l-menthol; preservatives such as p-hydroxybenzoate; Purified water; And other suitable fillers may be added.

In the case of a tape, a pressure-sensitive adhesive such as a styrene-isoprene-styrene block copolymer and an acrylate resin; Adhesive resins such as acrylic saturated hydrocarbon resins, hydrogenated rosin resins and terpene resins; Softeners such as liquid gums and liquid paraffin; Antioxidants such as dibutylhydroxytoluene; Polyhydric alcohols such as polyethylene glycol; Adsorption promoters such as oleic acid; Surfactants such as polyoxyethylene derivatives; And other suitable fillers may be added. In addition, water-absorbing polymers such as sodium polyacrylate and polyvinyl alcohol and a small amount of purified water can be added to the preparation of tapes containing water.

In the case of an aerosol agent, bases such as white petrolatum (Vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, isopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, vegetable oil, aliphatic alcohol and alcohol A solvent or a stabilizer such as; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin, carboxyvinyl polymers such as those used in creams, gels or lotions, xanthan gum, carboxymethyl Thickeners such as cellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Buffering agents; Sweetener suspension; Emulsifiers; Condiment; antiseptic; Adsorption promoters and other suitable fillers may be added.

For external powders, potato starch, rice starch, corn starch, fillers such as talc and zinc oxide, and other suitable additives may be added.

The external preparation for skin of the present invention may be prepared by mixing well-known ingredients with appropriate bases according to a well-known method for preparing external preparations, and the thus-prepared preparation is applied to lesions as required.

In another embodiment of the present invention, the present invention provides a cosmetic composition for improving or alleviating contact dermatitis comprising an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient: to provide:

[Chemical Formula 1]

.

.

In another embodiment of the present invention, the cosmetic composition is characterized by alleviating the inflammatory reaction.

In another embodiment of the present invention, the pharmaceutical composition is characterized by inhibiting an edema response.

In another embodiment of the present invention, the eriodictyol in the cosmetic composition may be 0.000001 to 1 wt% of the total weight of the cosmetic composition.

In another embodiment of the present invention, the eriodictyol in the cosmetic composition may be contained in an amount of 0.00001 to 0.01% by weight of the total cosmetic composition.

In another embodiment of the present invention, the eriodictyol in the cosmetic composition may be included in an amount of 0.00005 to 0.001% by weight of the total cosmetic composition.

The cosmetic composition of the present invention can be prepared in any formulations conventionally produced in the art and can be used in cosmetic formulations such as external ointments for skin, essence, whitening cream, lotion, emulsion, pack, general lotion, Serum, cosmetic soap, softening lotion, medicated lotion, hair tonic, whole body cleanser, oil gel and the like.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

In another embodiment of the present invention, there is provided a health functional food for improving or alleviating contact dermatitis comprising an eriodictyol compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient :

[Chemical Formula 1]

.

.

In another embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis characterized by relieving itching.

In another embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis characterized by alleviating an inflammatory reaction.

In another embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis characterized by suppressing edema reaction.

In another embodiment of the present invention, the health functional food is characterized in that the eriodictyol is 0.001 to 1 wt% of the total weight of the health functional food. will be.

Hereinafter, the present invention will be described in more detail with reference to the following Experimental Examples and Preparation Examples. It should be understood, however, that the same is by way of illustration and example only and is not intended to limit the scope of the present invention.

[Experimental Example 1] Induction of allergic contact dermatitis (preparation of experimental animals)

To induce allergic contact dermatitis, DNCB (2,4-dinitrochlorobenzene) was dissolved in a mixed solution of acetone and olive oil (mixing volume ratio 3: 1) as an antigen of delayed hypersensitivity to 1 w / v% in males by applying a 300 ㎕ the dorsal region ² ㎝ 2 of ICR mice were immune primary. Primary immunization After 4 days of curing, 250 μl of 0.5% DNCB was applied to the dorsal area, and the second immunization was performed by treating the same amount and the same amount continuously for about 2 weeks. In the case of the erio- dic thiol-coated group, 200 μL of 0.2 mg / mL was applied to the back side of the second DNCB once every other day.

[Experimental Example 2] Changes in scratching behavior

After the second antigen administration, video recording was performed at 24-hour intervals to check the degree of scratching caused by contact dermatitis. After the secondary application of DNCB, the back of the dorsal epidermis continued to develop, and scratching of the dorsal part of the subject continued to increase. In the group administered with the eriodic thiol, it was observed that after the third administration, the scratching was gradually reduced and recovered (see FIG. 1).

[Experimental Example 3] Skin sensory evaluation was carried out

After scoring with 0 points for symptomlessness, 1 point for symptom weakness, 2 points for normal symptom, 3 points for severe symptom for at least 5 items of irritated skin, edema, dry skin, edema, hematoma, The sum of the scores gave a score of at least 0 (no symptoms) to a maximum of 15 (all symptoms were severe). In the skin sensory evaluation, DNCB was applied to the contact dermatitis-induced group, the score increased gradually to 13 points. However, in the group treated with eriodic thiol, (See FIG. 2).

[Experimental Example 4] Changes in the thickness of dorsal epidermis (confirmed dorsal epidermal edema)

The dorsal epidermal thickness was determined by hematoxylin and eosin staining after dorsal epidermal tissue extraction. After the second application of DNCB, edema of the dorsal epidermis continuously occurred and the thickness was increased. In the group administered with ericodic thiol, edema was significantly alleviated from the third administration, and the result shows that the erodic thiol has an anti-inflammatory effect (see FIG. 3).

[Experimental Example 5] Changes in serum IgE

Blood IgE levels were measured at 450 nm using an IgE ELISA kit for mice. The concentration of IgE was increased more than 3 times in DNCB group compared to normal group, but IgE was decreased in DNCB group and erio - dictol. As a result, it was confirmed that the eriodic thiol caused the decrease of the allergic reaction due to the rise of the immunoglobulin (see FIG. 4).

Production Example 1. Cream

A. Remuneration

0.2% by weight of erythorbic thiol

Stearic acid 10.0

Stearyl alcohol 4.0

Butyl stearate 8.0

Stearic acid monoglycerin ester 2.0

Vitamin E acetate 0.5

Vitamin A palmitate 0.1

Octylmethoxycinnamate 2.0

Macadamia Nuts Milk 1.0

Tea Tree Oil 1.0

Fragrance 0.4

Antiseptic

B. Award

0.2% by weight of erythorbic thiol

Glycerin 4.0

1,2-pentadiol 3.0

Sodium hyaluronate 1.0

Potassium hydroxide 2.0

Magnesium ascorbic acid phosphate 0.1

L-arginine hydrochloride 0.01

0.0 >

Purified water balance

quite

The oil phase part of A and the water phase part of B are completely melted by heating them at 70 占 폚. Add phase A to phase B and emulsify with emulsifier. The emulsion was cooled with a heat exchanger to obtain a cream.

Production Example 2. Milk

A. Remuneration

0.2% by weight of erythorbic thiol

Squalane 5.0

Oleylate 3.0

Vaseline 2.0

Sorbitan sesquioleic acid ester 0.8

Polyoxyethylene oleyl ether 1.2

Evening Primrose Oil 0.5

Fragrance 0.3

Antiseptic

B. Award

0.2% by weight of erythorbic thiol

1,3-butylene glycol 4.5

Ethanol 3.0

Carboxyvinyl polymer 0.2

Potassium hydroxide 0.1

L-Aspartate 0.01

0.0 > 0.05 < / RTI &

Purified water balance

quite

A milky lotion was obtained according to Production Example 1.

Production Example 3. Lotion

A. Alcohol phase

5.0% by weight of ethanol

POE oleyl alcohol ether 2.0

Fragrance 0.05

B. Award

0.2% by weight of erythorbic thiol

1,3-butylene glycol 9.5

Sodium pyrrolidonecarboxylate 0.5

Nicotinic acid amide 0.3

Glycerin 5.0

Dimorpholinopyridadinone 0.1

Purified water balance

quite

The alcohol phase of A was added to the aqueous phase of B and solubilized to obtain a lotion.

Production Example 4. Latex

0.2% by weight of erythorbic thiol

Cetyl alcohol ether 1.0

Silicone KF96 (20cs) 2.0

Liquid paraffin 3.0

Propylene glycol 5.0

Glycerin 2.0

Ethyl alcohol 5.0

Carboxyvinyl polymer 0.3

Hydroxypropylcellulose 0.1

2-aminomethylpropanol 0.1

Vitamin A Acid 0.05

Alkylene oxide derivative 2.0

0.1

Trehalose 1.0

Antiseptic

Fragrance quantity

Distilled water balance

quite

As the prescription, the emulsion was prepared by a commercial method.

Manufacturing Example 5. Convergent lotion

0.2% by weight of erythorbic thiol

Dipropylene glycol 2.0

Citric acid 0.03

Sodium citrate 0.05

Alkylene oxide derivative 0.1

Ethyl alcohol 5.0

Polyoxyethylene (15 mole addition) oleyl alcohol ether 0.5

0.03

Trehalose 0.5

Antiseptic

Fragrance quantity

Distilled water balance

quite

Lotions were prepared by the commercial method under the above prescription.

Production Example 6. Cream

A. Remuneration

2.0% by weight of ethanol

Vaseline 2.0

Squalane 20.0

Glycerin mono fatty acid ester 2.0

Tween60 3.0

Isopropylmyristate 6.0

Stearyl glycyrrhizinate 1 0.5

Glycerin mono-2-ethylhexanoyl-diframethoxycinnamate 0.05

4-methoxy-4'-t-butyldibenzoylmethane 0.05

BHT 0.01

Preservative 0.3

Fragrance 0.2

B. Award

0.2% by weight of erythorbic thiol

Glycerin 10.0

Propylene glycol 5.0

Alkylene oxide derivative 0.1

Hydroxyproline 0.05

Trehalose 5.0

Sodium edetate 0.1

Potassium hydroxide 1.0

Distilled water balance

Production Example 7. Preparation of powder

Eliodic thiol 0.5 mg

Sucrose 100 mg

Talc 10 mg

The above components are powdered and mixed, and filled in an airtight container to prepare a powder.

Preparation Example 8. Preparation of tablets

Eliodic thiol 0.5 mg

Starch 100 mg

Sucrose 100 mg

Magnesium stearate 2 mg

The tablets are prepared by mixing the above components according to a conventional method for producing tablets and then tableting them.

Preparation Example 9. Preparation of capsules

Eliodic thiol 0.5 mg

Crystalline cellulose 3 mg

Lactose 15 mg

1 mg of magnesium stearate

The above components are mixed according to a conventional method for preparing a capsule, and then filled in a gelatin capsule to prepare a capsule.

Production Example 10. Preparation of Granules

Eliodic thiol 0.5 mg

Soybean extract 50 mg

Glucose 200 mg

Starch 500 mg

After mixing the above components, 100 mL of 30% ethanol is added, and the mixture is dried at 60 ° C to form granules, which are filled in a capsule to prepare granules.

Production Example 11. Preparation of a pellet

Eliodic thiol 0.5 mg

Lactose 1,500 mg

Glycerin 1,500 mg

Starch 980 mg

After mixing the above components, they are prepared so as to be 4 g per one ring according to a conventional method for producing a pellet.

Production Example 12. Preparation of injection

Eliodic thiol 0.5 mg

180 mg mannitol

Sterile sterilized drinking water 2,970 mg

Na ₂ HPO _{4 12} H ₂ O 30 mg

(2 mL) per 1 ampoule according to a conventional injection preparation method.

Production Example 13. Production of liquid agent

Eliodic thiol 0.5 mg

10,000 mg per isomerization

Mannitol 5,000 mg

Purified water quantity

Dissolving the above components in purified water according to a usual liquid preparation method, adding an appropriate fragrance, filling the bottle and sterilizing it.

Claims (24)

A pharmaceutical composition for preventing or treating contact dermatitis comprising an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Chemical Formula 1]

.
The method according to claim 1,
A pharmaceutical composition for preventing or treating contact dermatitis, wherein said pharmaceutical composition alleviates itching.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits an inflammatory reaction.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits edema. ≪ RTI ID = 0.0 > 21. < / RTI >
The method according to claim 1,
Wherein the contact dermatitis is contact dermatitis due to contact with an external substance.
The method according to claim 1,
Wherein the eriodictyol in the pharmaceutical composition is 0.001-10 wt% of the total weight of the pharmaceutical composition.
An external skin preparation for preventing or treating contact dermatitis comprising, as an active ingredient, an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof:
[Chemical Formula 1]

.
8. The method of claim 7,
Wherein said pharmaceutical composition alleviates itching. ≪ RTI ID = 0.0 > 11. < / RTI >
8. The method of claim 7,
Wherein said pharmaceutical composition inhibits an inflammatory reaction. ≪ RTI ID = 0.0 > 11. < / RTI >
8. The method of claim 7,
Wherein the pharmaceutical composition inhibits edema. ≪ RTI ID = 0.0 > 11. < / RTI >
8. The method of claim 7,
Wherein the external preparation for skin is any one selected from the group consisting of an ointment, a cream, a lotion, a liquid, a dressing, a patch, a foaming agent, a tape agent, an aerosol agent, Therapeutic skin external preparation.
8. The method of claim 7,
Wherein the eriodictyol in the external preparation for skin is 0.0001 to 5 wt% of the total weight of the external preparation for skin.
A cosmetic composition for improving or alleviating contact dermatitis comprising an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Chemical Formula 1]

.
14. The method of claim 13,
The cosmetic composition for improving or alleviating contact dermatitis is characterized in that the cosmetic composition alleviates itching.
14. The method of claim 13,
A cosmetic composition for improving or alleviating contact dermatitis characterized in that the cosmetic composition alleviates an inflammatory reaction.
14. The method of claim 13,
Wherein said pharmaceutical composition alleviates swelling. ≪ Desc / Clms Page number 24 >
14. The method of claim 13,
A cosmetic composition for improving or alleviating contact dermatitis, wherein the eriodictyol in the cosmetic composition is 0.000001 to 1 wt% of the total weight of the cosmetic composition.
14. The method of claim 13,
The cosmetic composition for improving or alleviating contact dermatitis according to claim 1, wherein the eriodictyol in the cosmetic composition is 0.00001 to 0.01 wt% of the total weight of the cosmetic composition.
14. The method of claim 13,
Wherein the eriodictyol in the cosmetic composition is 0.00005 to 0.001 wt% of the total weight of the cosmetic composition.
A health functional food for improving or alleviating contact dermatitis comprising an eriodictyol compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Chemical Formula 1]

.
21. The method of claim 20,
Wherein said health functional food alleviates itching. ≪ RTI ID = 0.0 > 18. < / RTI >
21. The method of claim 20,
Wherein said health functional food alleviates an inflammatory reaction.
21. The method of claim 20,
Wherein said health functional food alleviates edema. ≪ RTI ID = 0.0 > 18. < / RTI >
21. The method of claim 20,
The health functional food for improving or alleviating contact dermatitis, wherein the eriodictyol in the health functional food is 0.001 to 1% by weight of the total health functional food.

Images